

NOTICE

ALTERNATIVE MEDICATION AUTHORIZATION

An Act respecting prescription drug insurance (chapter A-29.01, s. 60.1)

I hereby authorize the temporary use of the following alternative medication:

99113715	<i>Olmesartan medoxomil</i>		1	20 mg	Caps.		
----------	---------------------------------	--	---	-------	-------	--	--

until the following medications, appearing on the *List of Medications* attached to the *Regulation respecting the List of medications covered by the basic prescription drug insurance plan*, are no longer out of stock:

02442191	<i>Act Olmesartan</i>	ActavisPhm	30	20 mg	Tab.	8.95	0.2984
02453452	<i>Apo-Olmesartan</i>	Apotex	30 100	20 mg	Tab.	8.95 29.84	0.2984
02443864	<i>Auro-Olmesartan</i>	Aurobindo	30 100	20 mg	Tab.	8.95 29.84	0.2984
02469812	<i>GLN-Olmesartan</i>	Glenmark	30	20 mg	Tab.	8.95	0.2984
02461641	<i>Jamp-Olmesartan</i>	Jamp	30 100	20 mg	Tab.	8.95 29.84	0.2984
02488744	<i>Olmesartan</i>	Pro Doc	30 100	20 mg	Tab.	8.95 29.84	0.2984
02318660	<i>Olmetec</i>	Merck	30	20 mg	Tab.	30.49	1.0163
02461307	<i>pms-Olmesartan</i>	Phmscience	30 100	20 mg	Tab.	8.95 29.84	0.2984
02471353	<i>Riva-Olmesartan</i>	Riva	30 100	20 mg	Tab.	8.95 29.84	0.2984
02443414	<i>Sandoz Olmesartan</i>	Sandoz	30 100	20 mg	Tab.	8.95 29.84	0.2984

This notice has effect retroactively from 5 November 2019.

Québec, 18 November 2019

ORIGINAL SIGNED by:

MARCO THIBAUT
President and Chief Executive Officer
Régie de l'assurance maladie du Québec

Publication of this notice on the website of the Régie de l'assurance maladie du Québec imparts authentic value to it.